CMB-401 Biosimilar – Anti-MUC1, CD227 mAb – Research Grade

Description of CMB-401 Biosimilar - Anti-MUC1, CD227 mAb - Research Grade

CMB-401 Biosimilar: A Revolutionary Antibody Targeting MUC1 and CD227

CMB-401 Biosimilar is a cutting-edge antibody that has been developed as a biosimilar to the existing anti-MUC1, CD227 monoclonal antibody (mAb). This biosimilar is a highly specific and potent therapeutic agent that targets two important cancer biomarkers – MUC1 and CD227. In this article, we will delve into the structure, activity, and application of CMB-401 Biosimilar in detail.

Structure of CMB-401 Biosimilar

CMB-401 Biosimilar is a recombinant humanized monoclonal antibody that has been engineered to mimic the structure and function of the original anti-MUC1, CD227 mAb. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The antibody has a unique Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to the target antigens, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

The amino acid sequence of CMB-401 Biosimilar has been optimized for maximum affinity and specificity towards MUC1 and CD227. It has been extensively characterized through various analytical techniques, such as mass spectrometry and chromatography, to ensure consistency and quality.

Activity of CMB-401 Biosimilar

CMB-401 Biosimilar has been designed to specifically target MUC1 and CD227, which are overexpressed in various types of cancer, including breast, lung, and pancreatic cancer. MUC1 is a transmembrane glycoprotein that is aberrantly expressed in cancer cells, and its overexpression has been linked to tumor growth, invasion, and metastasis. CD227, also known as MUC1-C, is the intracellular domain of MUC1 and plays a critical role in promoting cancer cell survival and resistance to therapy.

By binding to MUC1 and CD227, CMB-401 Biosimilar blocks their signaling pathways and inhibits their pro-tumorigenic effects. This leads to a decrease in cancer cell proliferation, migration, and survival, ultimately resulting in tumor regression. In addition, the Fc region of the antibody can activate immune cells, such as natural killer cells and macrophages, to directly kill cancer cells through ADCC and CDC.

Application of CMB-401 Biosimilar

CMB-401 Biosimilar has shown promising results in preclinical studies, demonstrating its potential as a therapeutic agent for various types of cancer. It has been shown to be effective in inhibiting tumor growth and metastasis in animal models of breast, lung, and pancreatic cancer. In addition, it has also shown potential for combination therapy with other anti- cancer agents, such as chemotherapy and targeted therapy.

Currently, CMB-401 Biosimilar is being evaluated in clinical trials for the treatment of breast and lung cancer, with plans for further expansion to other cancer types. The biosimilar is being developed as a research-grade product, with the aim of obtaining regulatory approval for clinical use in the near future.

Conclusion

CMB-401 Biosimilar is a highly promising antibody that targets two important cancer biomarkers – MUC1 and CD227. Its unique structure and optimized amino acid sequence make it a potent and specific therapeutic agent for various types of cancer. With ongoing clinical trials and plans for further development, CMB-401 Biosimilar has the potential to revolutionize cancer treatment and improve patient outcomes.

Keywords: CMB-401 Biosimilar, anti-MUC1, CD227 mAb, biosimilar, antibody, therapeutic target, cancer biomarker, preclinical studies, clinical trials, combination therapy.